As the use of osteoporosis medications such as bisphosphonates and other antiresorptive therapies continues to increase worldwide, dental professionals must be prepared to recognize risk factors, implement preventive strategies, and manage affected patients safely and effectively.
In this exclusive interview, Dr. Hassan Moghadam provides valuable insights into the relationship between osteoporosis medications and the development of osteonecrosis of the jaw.
Through an evidence-based discussion, he explores the biological mechanisms behind ONJ, current risk assessment protocols, and the latest recommendations for dental treatment planning in patients receiving antiresorptive therapy.
Throughout the interview, key topics are addressed, including patient evaluation, medical history assessment, preventive dental care before and during osteoporosis treatment, surgical considerations, and interdisciplinary collaboration between dentists and physicians.
Special attention is given to minimizing complications while maintaining optimal oral health outcomes.
This educational content is highly relevant for general dentists, oral surgeons, periodontists, implantologists, dental specialists, and students seeking to enhance their understanding of medication-related osteonecrosis and its impact on clinical decision-making.
👉 We invite you to watch the full interview shared in this post and gain practical, up-to-date knowledge on Osteonecrosis of the Jaw (ONJ) and osteoporosis medications with Dr. Hassan Moghadam.
